Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036 for the Treatment of Glaucoma
![](/46/pdcnewsitem/03/44/86/drtfZu1Q2YavrFr.png)
Isarna Therapeutics has announced the presentation of preclinical data for its lead candidate ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, currently in Phase I development for the treatment of advanced-stage glaucoma. Isarna presented supporting preclinical results in one podium presentation and two poster publications at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held 3–7 May in Denver, Colorado.
As described in the podium presentation, ISTH0036 was administered to evaluate its therapeutic potential in murine models of glaucoma filtration surgery (GFS) and laser-induced choroidal neovascularization (CNV). In the murine GFS model, upon intraocular administration, ISTH0036 was able to significantly prolong bleb survival, as compared to control oligonucleotide- and saline-treated eyes. In addition, ISTH0036 was able to significantly decrease the extent of fibrosis in the bleb area in a sequence-specific manner.
Furthermore, in a murine CNV model, intravitreal administration of ISTH0036 was able to significantly reduce (40%) the process of angiogenesis, as compared to saline- and control oligonucleotide-treated eyes. This observation may open up development opportunities beyond glaucoma.
Also presented at the conference, two posters described the overall preclinical profile and the testing of ISTH0036 in which it successfully demonstrated excellent cellular uptake, potent TGF-ß2 mRNA downregulation (target engagement) in cell-based assays and in relevant tissues of the eye. Long-lasting tissue distribution was consistent with the observed target engagement.
“We have clearly demonstrated in these animal models that intraocular administration of ISTH0036 leads to biological responses consistent with the expected molecular mechanism of action and with observed efficient and long-lasting distribution in relevant eye tissues,” said Dr. Michel Janicot, Head of Preclinical Research and Development at Isarna. “These preclinical data support the compound’s potential to protect glaucoma patients’ vision and we hope to reproduce these results in our ongoing clinical evaluation of the compound. In addition, based on these data we see several other high medical need diseases that could potentially benefit from TGF-ß-targeted treatment.”
Several diseases in ophthalmology have been linked to the modulation of TGF-ß, among them are glaucoma, proliferative vitreoretinopathy, diabetic retinopathy and corneal diseases. TGF-ß2 has specifically been identified as having a critical role in the pathophysiology of glaucoma affecting changes in the ocular outflow region that can lead to open-angle glaucoma and has been linked in addition to having a direct, toxic effect on the optic nerve head.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance